{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.2","upperLimit":"7.4","value":"6.4"},{"groupId":"OG001","lowerLimit":"4.6","upperLimit":"6.9","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"},{"groupId":"OG001","value":"71"}],"units":"Participants"}],"description":"Time from the date of randomization to the date of death from any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"Gemcitabine + Paclitaxel until progression\n\nGemcitabine: 1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.\n\nPaclitaxel: 80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.","id":"OG000","title":"GEMPAX"},{"description":"Gemcitabine alone until progression\n\nGemcitabine: 1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.","id":"OG001","title":"Control"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Until death (life expectancy around 12 months)","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}